The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5

被引:99
|
作者
Zwick, MB
Komori, HK
Stanfield, RL
Church, S
Wang, M
Parren, PWHI
Kunert, R
Katinger, H
Wilson, IA
Burton, DR
机构
[1] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[4] Univ Nat Resources, Inst Appl Microbiol, Vienna, Austria
关键词
D O I
10.1128/JVI.78.6.3155-3161.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human monoclonal antibody 2F5 neutralizes primary human immunodeficiency virus type 1 (HfV-1) with rare breadth and potency. A crystal structure of a complex of 2F5 and a peptide corresponding to its core epitope on gp41, ELDKWAS, revealed that the peptide interacts with residues at the base of the unusually long (22-residue) third complementarity-determining region of the heavy chain (CDR H3) but not the apex. Here, we perform alanine-scanning mutagenesis across CDR H3 and make additional substitutions of selected residues to map the paratope of Fab 2F5. Substitution of residues from the base of the H3 loop or from CDRs H1, H2, and L3, which are proximal to the peptide, significantly diminished the affinity of Fab 2F5 for gp41 and a short peptide containing the 2F5 core motif. However, nonconservative substitutions to a phenylalanine residue at the apex of the H3 loop also markedly decreased 2F5 binding to both gp41 and the peptide, suggesting that recognition of the core epitope is crucially dependent on features at the apex of the H3 loop. Furthermore, substitution at the apex of the H3 loop had an even more pronounced effect on the neutralizing activity of 2F5 against three sensitive HIV-1. These observations present a challenge to vaccine strategies based on peptide mimics of the linear epitope.
引用
收藏
页码:3155 / 3161
页数:7
相关论文
共 50 条
  • [21] Fusion Peptide Effects on Epitope Recognition At Membrane Surfaces by the Broadly Neutralizing Anti-HIV-1 2f5 Monoclonal Antibody
    Huarte, Nerea
    BIOPHYSICAL JOURNAL, 2010, 98 (03) : 91A - 91A
  • [22] Fusion peptide effects on epitope recognition at membrane surfaces by the broadly neutralizing anti-HIV-1 2F5 monoclonal antibody
    Huarte, Nerea
    Araujo, Aitziber
    Arranz, Rocio
    Valpuesta, Jose M.
    Nieva, Jose L.
    CHEMISTRY AND PHYSICS OF LIPIDS, 2010, 163 : S51 - S51
  • [23] Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors
    Rusconi, S
    Berlusconi, A
    Papagno, L
    Colombo, MC
    deMaddalena, C
    Riva, A
    Bagnarelli, P
    Balotta, C
    Galli, M
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 85 (03): : 320 - 323
  • [24] Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12
    Wolbank, S
    Kunert, R
    Stiegler, G
    Katinger, H
    JOURNAL OF VIROLOGY, 2003, 77 (07) : 4095 - 4103
  • [25] The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate
    Conley, AJ
    Kessler, JA
    Boots, LJ
    McKenna, PM
    Schleif, WA
    Emini, EA
    Mark, GE
    Katinger, H
    Cobb, EK
    Lunceford, SM
    Rouse, SR
    Murthy, KK
    JOURNAL OF VIROLOGY, 1996, 70 (10) : 6751 - 6758
  • [26] The immunoglobulin CH1 constant region modulates antigen binding affinity and functional activities of the broadly neutralizing 2F5 HIV specific antibody
    Daniela Tudor
    Anne-Sophie Drillet
    Isabelle Schwartz-Cornil
    Ruizhong Shen
    Phillip D Smith
    Morgane Bomsel
    Retrovirology, 7
  • [27] The immunoglobulin CH1 constant region modulates antigen binding affinity and functional activities of the broadly neutralizing 2F5 HIV specific antibody
    Tudor, Daniela
    Drillet, Anne-Sophie
    Schwartz-Cornil, Isabelle
    Shen, Ruizhong
    Smith, Phillip D.
    Bomsel, Morgane
    RETROVIROLOGY, 2010, 7 : 22 - 22
  • [28] Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent Anti-Human Immunodeficiency Virus Type 1 Activity
    Huet, Thierry
    Kerbarh, Olivier
    Schols, Dominique
    Clayette, Pascal
    Gauchet, Cecile
    Dubreucq, Guy
    Vincent, Loic
    Bompais, Heidi
    Mazinghien, Romain
    Querolle, Olivier
    Salvador, Arnaud
    Lemoine, Jerome
    Lucidi, Bruno
    Balzarini, Jan
    Petitou, Maurice
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 134 - 142
  • [29] Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L
    Hessell, Ann J.
    Rakasz, Eva G.
    Tehrani, David M.
    Huber, Michael
    Weisgrau, Kimberly L.
    Landucci, Gary
    Forthal, Donald N.
    Koff, Wayne C.
    Poignard, Pascal
    Watkins, David I.
    Burton, Dennis R.
    JOURNAL OF VIROLOGY, 2010, 84 (03) : 1302 - 1313
  • [30] In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth
    Shen, Xiaoying
    Parks, Robert J.
    Montefiori, David C.
    Kirchherr, Jennifer L.
    Keele, Brandon F.
    Decker, Julie M.
    Blattner, William A.
    Gao, Feng
    Weinhold, Kent J.
    Hicks, Charles B.
    Greenberg, Michael L.
    Hahn, Beatrice H.
    Shaw, George M.
    Haynes, Barton F.
    Tomaras, Georgia D.
    JOURNAL OF VIROLOGY, 2009, 83 (08) : 3617 - 3625